MoonLake Immunotherapeutics annual current ratio
2020
2021
2022
2023
2024
2025
MoonLake Immunotherapeutics Current Ratio Growth & History (MLTX)
MoonLake Immunotherapeutics's current ratio was 9.27 for fiscal 2025.
View full MoonLake Immunotherapeutics company overviewMoonLake Immunotherapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 9.27 | −11.84 | −56.08% |
| 2024 | 2024-12-31 | 21.11 | −30.48 | −59.08% |
| 2023 | 2023-12-31 | 51.59 | 41.61 | +416.90% |
| 2022 | 2022-12-31 | 9.98 | 9.52 | +2084.17% |
| 2021 | 2021-12-31 | 0.46 | −12.48 | −96.47% |
| 2020 | 2020-12-31 | 12.93 | — | — |
MoonLake Immunotherapeutics quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 12.56 | −4.09 | −24.56% |
| Q1 2026 | 2026-03-31 | 8.60 | −12.51 | −59.26% |
| Q4 2025 | 2025-12-31 | 9.27 | −11.84 | −56.08% |
| Q3 2025 | 2025-09-30 | 8.50 | −17.01 | −66.68% |
| Q2 2025 | 2025-06-30 | 16.65 | −27.07 | −61.92% |
| Q1 2025 | 2025-03-31 | 21.11 | −41.02 | −66.02% |
| Q4 2024 | 2024-12-31 | 21.11 | −30.48 | −59.08% |
| Q3 2024 | 2024-09-30 | 25.51 | −22.99 | −47.40% |
| Q2 2024 | 2024-06-30 | 43.71 | −27.26 | −38.41% |
| Q1 2024 | 2024-03-31 | 62.13 | 52.99 | +580.03% |
| Q4 2023 | 2023-12-31 | 51.59 | 41.61 | +416.90% |
| Q3 2023 | 2023-09-30 | 48.51 | 33.80 | +229.74% |
| Q2 2023 | 2023-06-30 | 70.97 | 45.47 | +178.26% |
| Q1 2023 | 2023-03-31 | 9.14 | 8.56 | +1494.95% |
| Q4 2022 | 2022-12-31 | 9.98 | 9.52 | +2084.17% |
| Q3 2022 | 2022-09-30 | 14.71 | 14.12 | +2409.99% |
| Q2 2022 | 2022-06-30 | 25.51 | 10.71 | +72.44% |
| Q1 2022 | 2022-03-31 | 0.57 | −23.76 | −97.65% |
| Q4 2021 | 2021-12-31 | 0.46 | −12.48 | −96.47% |
| Q3 2021 | 2021-09-30 | 0.59 | — | — |
| Q2 2021 | 2021-06-30 | 14.79 | — | — |
| Q1 2021 | 2021-03-31 | 24.33 | — | — |
| Q4 2020 | 2020-12-31 | 12.93 | — | — |
MoonLake Immunotherapeutics current ratio trends
Over the last five fiscal years, MoonLake Immunotherapeutics's current ratio decreased from 12.93 to 9.27, a change of −3.66. The latest reported quarter, Q2 2026, shows 12.56.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MoonLake Immunotherapeutics source filings ↗